CL2019000820A1 - Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134) - Google Patents

Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Info

Publication number
CL2019000820A1
CL2019000820A1 CL2019000820A CL2019000820A CL2019000820A1 CL 2019000820 A1 CL2019000820 A1 CL 2019000820A1 CL 2019000820 A CL2019000820 A CL 2019000820A CL 2019000820 A CL2019000820 A CL 2019000820A CL 2019000820 A1 CL2019000820 A1 CL 2019000820A1
Authority
CL
Chile
Prior art keywords
compounds
compositions
divisional application
arginase activity
inhibit arginase
Prior art date
Application number
CL2019000820A
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CL2019000820A1 publication Critical patent/CL2019000820A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UNA NUEVA CLASE DE COMPUESTOS QUE EXHIBEN ACTIVIDAD INHIBIDORA DE LA ACTIVIDAD HACIA LA ARGINASA, Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA INVENCIÓN. TAMBIÉN SE PROPORCIONAN EN EL PRESENTE DOCUMENTO LOS MÉTODOS PARA TRATAR EL CÁNCER CON LOS INHIBIDORES DE ARGINASA DE LA INVENCIÓN.
CL2019000820A 2015-10-30 2019-03-28 Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134) CL2019000820A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
CL2019000820A1 true CL2019000820A1 (es) 2019-08-09

Family

ID=58631120

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2018001134A CL2018001134A1 (es) 2015-10-30 2018-04-27 Composiciones y métodos para inhibir la actividad arginasa
CL2019000820A CL2019000820A1 (es) 2015-10-30 2019-03-28 Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019000819A CL2019000819A1 (es) 2015-10-30 2019-03-28 Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019000821A CL2019000821A1 (es) 2015-10-30 2019-03-28 Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018001134A CL2018001134A1 (es) 2015-10-30 2018-04-27 Composiciones y métodos para inhibir la actividad arginasa

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2019000819A CL2019000819A1 (es) 2015-10-30 2019-03-28 Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019000821A CL2019000821A1 (es) 2015-10-30 2019-03-28 Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)

Country Status (36)

Country Link
US (4) US10065974B2 (es)
EP (3) EP4011887B1 (es)
JP (3) JP6833844B2 (es)
KR (2) KR20220118559A (es)
CN (4) CN113150015A (es)
AU (3) AU2016343656B2 (es)
BR (3) BR122020022280B1 (es)
CA (1) CA3003271A1 (es)
CL (4) CL2018001134A1 (es)
CO (1) CO2018004750A2 (es)
CR (3) CR20210389A (es)
CY (1) CY1123557T1 (es)
DK (1) DK3368541T3 (es)
EA (1) EA038276B1 (es)
EC (1) ECSP18040250A (es)
ES (2) ES2808988T3 (es)
HK (1) HK1252560A1 (es)
HR (1) HRP20201046T1 (es)
HU (1) HUE054972T2 (es)
IL (3) IL258731B (es)
LT (1) LT3368541T (es)
MA (2) MA50636A (es)
MD (1) MD3368541T2 (es)
MX (1) MX2018005294A (es)
MY (1) MY201783A (es)
NZ (1) NZ742742A (es)
PH (1) PH12018500899A1 (es)
PL (1) PL3368541T3 (es)
PT (1) PT3368541T (es)
RS (1) RS60695B1 (es)
SG (4) SG11201802961PA (es)
SI (1) SI3368541T1 (es)
TW (3) TWI734630B (es)
UA (1) UA125289C2 (es)
WO (1) WO2017075363A1 (es)
ZA (4) ZA201803556B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348422B (es) 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
SI2632927T1 (sl) 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
SI3559009T1 (sl) * 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
PE20200339A1 (es) 2017-05-12 2020-02-14 Calithera Biosciences Inc Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
CN117180290A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
IL276813B2 (en) 2018-03-05 2024-09-01 Arcus Biosciences Inc History of 4-substituted 5-amino-octahydrocyclopenta[c]pyrrole-5-carboxylic acid, their pharmaceutical combinations and their use for the treatment of diseases
US20210040127A1 (en) * 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
TWI723366B (zh) 2018-03-29 2021-04-01 波蘭商昂科艾倫迪治療法股份公司 二肽哌啶衍生物
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020160707A1 (en) * 2019-02-06 2020-08-13 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
EP3962897A4 (en) * 2019-05-02 2022-12-14 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme LLC ARGINASE INHIBITORS AND METHODS OF USE
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022016195A1 (en) 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
US20240317744A1 (en) 2023-03-13 2024-09-26 Incyte Corporation Bicyclic Ureas As Kinase Inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2296080C (en) 1997-07-29 2005-02-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
WO1999019295A1 (en) 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
KR20150115959A (ko) * 2007-10-12 2015-10-14 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
RS58965B1 (sr) * 2009-01-26 2019-08-30 Univ Pennsylvania Inhibitori arginaze i postupci upotrebe
MX348422B (es) 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
SI2632927T1 (sl) * 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
JP5993459B2 (ja) 2011-10-19 2016-09-14 マーズ インコーポレイテッド アルギナーゼ阻害剤およびそれらの治療用途
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
IN2014DN09678A (es) 2012-04-18 2015-07-31 Mars Inc
US9717731B2 (en) * 2012-11-02 2017-08-01 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
EP3060251A4 (en) * 2013-10-25 2017-12-06 Pharmacyclics LLC Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
KR20170129896A (ko) * 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
EP3313410A4 (en) * 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
IL258731B (en) 2021-04-29
JP2021075543A (ja) 2021-05-20
BR122020022275B1 (pt) 2022-05-03
US20170121352A1 (en) 2017-05-04
CN108271371A (zh) 2018-07-10
ECSP18040250A (es) 2018-10-31
PT3368541T (pt) 2020-07-06
CL2019000821A1 (es) 2019-08-09
SG10201911402YA (en) 2020-02-27
HK1252560A1 (zh) 2019-05-31
AU2020286278B2 (en) 2022-03-17
HUE054972T2 (hu) 2021-10-28
CN113150016A (zh) 2021-07-23
SG10201911406TA (en) 2020-01-30
IL258731A (en) 2018-06-28
ZA201907093B (en) 2021-03-31
EP4011887A1 (en) 2022-06-15
AU2020286278A1 (en) 2021-01-14
PL3368541T3 (pl) 2020-11-02
BR112018008746A8 (pt) 2019-02-26
TW201726692A (zh) 2017-08-01
BR112018008746A2 (pt) 2018-10-30
TWI710565B (zh) 2020-11-21
SG11201802961PA (en) 2018-05-30
BR112018008746B1 (pt) 2021-11-16
IL281503A (en) 2021-04-29
RS60695B1 (sr) 2020-09-30
WO2017075363A1 (en) 2017-05-04
CR20210390A (es) 2021-10-19
MA50636A (fr) 2021-04-14
ES2808988T3 (es) 2021-03-02
TWI734630B (zh) 2021-07-21
EA201891057A1 (ru) 2018-12-28
TW202110858A (zh) 2021-03-16
SI3368541T1 (sl) 2020-10-30
CL2018001134A1 (es) 2018-10-26
US10065974B2 (en) 2018-09-04
MX2018005294A (es) 2018-09-21
EP3693375B1 (en) 2022-02-16
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
CN113201002A (zh) 2021-08-03
CN108271371B (zh) 2021-02-09
AU2016343656B2 (en) 2020-09-17
DK3368541T3 (da) 2020-06-29
BR122020022280B1 (pt) 2022-05-03
HRP20201046T1 (hr) 2020-10-16
IL288225A (en) 2022-01-01
EP3368541A1 (en) 2018-09-05
JP6833844B2 (ja) 2021-02-24
US10844080B2 (en) 2020-11-24
UA125289C2 (uk) 2022-02-16
TW202146028A (zh) 2021-12-16
CO2018004750A2 (es) 2018-10-31
ES2910928T3 (es) 2022-05-17
CL2019000819A1 (es) 2019-08-09
EP3368541A4 (en) 2019-07-17
CN113150015A (zh) 2021-07-23
KR102434308B1 (ko) 2022-08-19
AU2016343656A1 (en) 2018-06-07
TWI775556B (zh) 2022-08-21
ZA201907091B (en) 2021-05-26
JP2022071010A (ja) 2022-05-13
US10851118B2 (en) 2020-12-01
CA3003271A1 (en) 2017-05-04
ZA201907092B (en) 2021-04-28
KR20220118559A (ko) 2022-08-25
US20210061822A1 (en) 2021-03-04
US20200223872A1 (en) 2020-07-16
MD3368541T2 (ro) 2020-09-30
EP4011887B1 (en) 2024-07-31
JP7032583B2 (ja) 2022-03-08
EP3368541B1 (en) 2020-05-27
PH12018500899A1 (en) 2018-10-29
CR20210389A (es) 2021-09-16
US20180346489A1 (en) 2018-12-06
JP2018533582A (ja) 2018-11-15
KR20180084063A (ko) 2018-07-24
AU2022203703A1 (en) 2022-06-16
LT3368541T (lt) 2020-09-25
IL281503B (en) 2022-01-01
CY1123557T1 (el) 2022-03-24
EA038276B1 (ru) 2021-08-04
MY201783A (en) 2024-03-18
CR20180282A (es) 2018-11-30
MA43131B1 (fr) 2020-07-29
ZA201803556B (en) 2021-02-24
EP3693375A1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CL2020002919A1 (es) Inhibidores de mcl-1
CR20150316A (es) Compuestos y sus métodos de empleo
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CL2020000169A1 (es) Compuestos macrocíclicos y usos de los mismos.
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CO2017001994A2 (es) Compuestos activos hacia bromodominios
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018002699A1 (es) Profármacos de fármacos citotóxicos que tienen grupos enzimáticamente escindibles.
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.